The Nobel prize in medicine now puts autophagy inhibition and Sprint Bioscience’s VPS34 project in the spotlight. Read more about it in the latest Q2-update analysis from Analyst Group.
“- One more billion-deal signed that demonstrates quality and efficiency
– Qualitymarker within the industry increases the probability of success
– Positive operating profit for H1 2016
– Broad pipeline in oncology and diabetes
– The effective business model allows Sprint Bioscience to take a project from start to commercialization and a closed billion contract in a short time
– The company’s present value amounts to 504 million”
You can download the full analysis (available in Swedish) here.
